AC
SONM icon

Aristides Capital’s DNA X Inc SONM Stock Holding History

Aristides Capital’s Portfolio SONM Stock Details SONM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7
Closed -$43K – 228
2019
Q4 		$43K Buy
+7
New +$34.5K 0.03% 219

Other funds holding SONM

NC
Nokomis Capital Dallas, Texas $349M AUM 75.66% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PA Capital Richmond, Virginia $142M AUM 46.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return

Aristides Capital's SONM Position: Q1 2020 in Review

Aristides Capital sold out of DNA X Inc (SONM) in Q1 2020, closing a stake of 7 shares — an estimated $43K sold.

Aristides Capital first reported a position in SONM in Q4 2019 and held it in 1 quarter. The position peaked at $43K in Q4 2019. 37 funds tracked by Wall St. Rank hold SONM as of Q1 2020.

  • Aristides Capital reported no remaining DNA X Inc position as of Q1 2020 after selling out during the quarter.
  • Aristides Capital sold 7 DNA X Inc shares in Q1 2020, an estimated $43K.
  • Aristides Capital first reported a position in DNA X Inc in Q4 2019 and held it in 1 quarter.
  • Aristides Capital's DNA X Inc position peaked at $43K in Q4 2019.
  • 37 funds tracked by Wall St. Rank held DNA X Inc as of Q1 2020.

Based on Aristides Capital's 13F filing for Q1 2020, filed 15 May 2020.